Screen Reader Mode Icon
PART 1 – GENERAL INFORMATION ON QUESTIONNAIRE
AIM OF QUESTIONNAIRE
The purpose of this questionnaire is to learn about  International Society of Psychiatric Genetics (ISPG) members' attitudes towards, knowledge of, and experience with pharmacogenomic testing in mental health. This questionnaire is part of ongoing work from the Genetic Testing Committee of the ISPG. Data will inform the panel discussion of the Genetic Testing Town Hall at the World Congress of Psychiatric Genetics 2021.

CONSENT TO QUESTIONNAIRE
Your participation is voluntary. The survey was designed to be anonymous and your responses will remain confidential.  The survey will take approximately 15-20 minutes.  Clicking on the "I agree to participate" button below implies your consent. You may vacate the questionnaire at any time. Answers will only be recorded for the study after the "send”-button at the end of this survey was clicked.

 RESEARCHERS RESPONSIBLE FOR THE STUDY
This questionnaire was designed by members of the Genetic Testing Committee of the ISPG. It was submitted to the Conjoint Health Research Ethics Board (CHREB) at the University of Calgary, Canada. If you have any questions in relation to the questionnaire/study please contact:

Chad Bousman, MPH, PhD,  Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, and Community Health Sciences, University of Calgary, Canada (chad.bousman@ucalgary.ca);

Franziska Degenhardt, MD, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (franziska.degenhardt@lvr.de)

Question Title

* INFORMATION ON DATA COLLECTION, PROTECTION, AND USAGE
In order to reduce the chances of one respondent being identified, some questions offer a “grouped together answer”  (e.g., other in relation to gender; or geographic region that you work in). The link to this online questionnaire was sent to all current members of the ISPG. Questionnaire data will be  stored on a secure server at University of Calgary. Data will be shared between members of the Genetic Testing Committee for analyses, interpretation, and publication.  Results in aggregated form will be disseminated to stakeholders relevant for pharmacogenomic testing in clinical psychiatry (e.g. identified via open access publication and scientific conferences).

0 of 40 answered
 

T